2 enrolling by invitation. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| Prostate Cancer Patient Management With 18F-DCFPyL PET/CT 18F-DCFPyL PET/CT - Prostate Cancer | Phase 2 / Phase 3 | Enrolling by invitation | Sir Mortimer B. Davis - Jewish General Hospital | 1500 | 2018-06-22 | 2023-11-27 |
Prostatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Neoplasms (1)
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Nivolumab (1) · Prednisone (1) · abiraterone (1) · atezolizumab (1) · cabozantinib (1) · enzalutamide (1)
Exelixis (1) · Sir Mortimer B. Davis - Jewish General Hospital (1)
Canada (1) · United States (1)